Table 1.
Group | Dose (mg/kg) | n | ALT (U/L) | AST (U/L) | TBIL (μM) | DBIL (μM) | IBIL (μM) |
---|---|---|---|---|---|---|---|
CON | – | 8 | 33.50 ± 2.34 | 141.38 ± 3.72 | 3.55 ± 0.14 | 0.78 ± 0.06 | 2.67 ± 0.16 |
CON + RES | 15 | 5 | 32.02 ± 1.70## | 136.60 ± 1.75## | 3.10 ± 0.08## | 0.80 ± 0.04## | 2.30 ± 0.11## |
NAFLD | – | 8 | 67.45 ± 2.28** | 171.62 ± 3.20** | 6.34 ± 0.18** | 2.36 ± 0.38** | 3.96 ± 0.22** |
NAFLD + RES | 15 | 8 | 36.66 ± 1.14## | 143.38 ± 2.09## | 4.00 ± 0.17## | 1.25 ± 0.14## | 2.88 ± 0.13## |
NAFLD + STG | 10 | 8 | 32.74 ± 1.36## | 142.25 ± 3.01## | 3.72 ± 0.08## | 0.82 ± 0.04## | 2.90 ± 0.12## |
NAFLD + RSG | 5 | 8 | 29.79 ± 1.82## | 138.33 ± 3.42## | 3.80 ± 0.10## | 0.87 ± 0.06## | 2.93 ± 0.10## |
NAFLD + FLX | 2 | 8 | 62.02 ± 1.91# | 168.88 ± 2.20 | 5.48 ± 0.24## | 1.62 ± 0.25## | 3.79 ± 0.18 |
NAFLD + DNP | 1 | 8 | 62.19 ± 2.03 | 167.88 ± 3.06 | 5.34 ± 0.18## | 1.59 ± 0.13## | 3.78 ± 0.14 |
P < 0.001 compared with the CON group;
P < 0.05 and
P < 0.001 compared with the NAFLD model group.